Scientist II

Scientist II (Lentiviral Vector Expert — In Vivo Cell Therapy) Job description Immix Biopharma, Inc (NASDAQ:IMMX) Sacramento, CA Our 3 Core Values Intelligence Integrity Initiative What You’ll Do The development and production of lentiviral vectors necessary for gene transfer in research experiments and pre-clinical studies. Expertise in developing vectors that fit with individual project requirements; design and manufacture of novel vectors and purified recombinant retrovirus and lentivirus. Knowledge and proficiency with standard molecular biology cloning techniques. Skills and Experience we look for At least 2-3 years of experience in molecular biology techniques of cloning and viral vector construction In vivo lentiviral CAR-T construction Education Master’s Degree or PhD preferred Additional Information Flexible working environment Competitive reward including annual company bonus Eligibility for an option grant to subscribe to shares in Immix Biopharma, Inc Immix Biopharma, Inc. Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases. Our lead cell therapy is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201, currently being evaluated in the ongoing Phase 1b/2 NEXICART-1 (NCT04720313) clinical trial. NXC-201 has the potential to be the world’s first “Single-Day CRS” CAR-T, enabling the potential for a faster return home for patients and supporting ongoing expansion into autoimmune indications. NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma, and ODD by the European Commission (EMA) in multiple myeloma and AL Amyloidosis. Learn more at and #J-18808-Ljbffr Immix Biopharma (Nasdaq: IMMX)